Neon Therapeutics, Inc.
If you purchased Neon Therapeutics, Inc. securities and would like to join the action, please click "Join This Action" below.
NEON MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF NEON THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – NTGN
January 16, 2020.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Neon Therapeutics, Inc. (NASDAQ: NTGN) to BioNTech SE (“BioNTech”) for 0.063 American Depositary Shares of BioNTech for each share of Neon is fair to Neon shareholders. On behalf of Neon shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
The Neon merger investigation concerns whether Neon and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Neon shareholders; (2) determine whether BioNTech is underpaying for Neon; and (3) disclose all material information necessary for Neon shareholders to adequately assess and value the merger consideration.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.